We believe that the results of our study will provide clinical evidence and play an important role in the evaluation of the value of pembrolizumab and cemiplimab in the treatment of patients with advanced NSCLC with high PD-L1 expression. Here, CD274 is linked to non-small cell lung carcinoma.